

Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Pipeline Review, H1 2017

https://marketpublishers.com/r/M9480A14242EN.html

Date: June 2017

Pages: 25

Price: US\$ 3,500.00 (Single User License)

ID: M9480A14242EN

Abstracts

Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Pipeline Review, H1 2017

SUMMARY

According to the recently published report 'Mitogen Activated Protein Kinase Kinase Kinase Kinase 7 - Pipeline Review, H1 2017'; Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Mitogen-activated protein kinase kinase kinase 7 is an enzyme that is encoded by the MAP3K7 gene. It plays an important role in the cascades of cellular responses evoked by changes in the environment. It mediates signal transduction of TRAF6, various cytokines interleukin-1 (IL-1), transforming growth factor-beta (TGFB), TGFB-related factors like BMP2 and BMP4, toll-like receptors (TLR), tumor necrosis factor receptor CD40 and B-cell receptor (BCR).

The report 'Mitogen Activated Protein Kinase Kinase Kinase 7 - Pipeline Review, H1 2017' outlays comprehensive information on the Mitogen Activated Protein Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule



type; that are being developed by Companies/Universities.

It also reviewsalso reviews key players involved in Mitogen Activated Protein Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Preclinical and Discovery stages are 2 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Immunology, Oncology, Genetic Disorders and Ophthalmology which include indications Inflammation, Chronic Inflammation, Neonatal Onset Multisystem Inflammatory Disease, Ovarian Cancer, Pancreatic Cancer and Proliferative Vitreoretinopathy (PVR).

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25)

The report reviews Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Mitogen Activated Protein Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) targeted therapeutics and enlists all their major and minor projects



The report assesses Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) development landscape



Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope



Contents

Introduction

Global Markets Direct Report Coverage

Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta

Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Overview

Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta

Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta

Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta

Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Companies Involved in Therapeutics

Development

Astellas Pharma Inc

Chugai Pharmaceutical Co Ltd

Confluence Life Sciences Inc

Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta

Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Drug Profiles

Drug to Inhibit TAK1 for Proliferative Vitreoretinopathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit TAK1 for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit TAK1 for Ovarian Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TAK1 for Arthritis, Genetic Disorders, Chronic Inflammation



and Pancreatic Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit TAK1 for Inflammation and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta

Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Dormant Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



Dormant Projects, H1 2017

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indication, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products under Investigation by Universities/Institutes, H1 2017
Products under Investigation by Universities/Institutes, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Pipeline by Astellas Pharma Inc, H1 2017
Pipeline by Chugai Pharmaceutical Co Ltd, H1 2017
Pipeline by Confluence Life Sciences Inc, H1 2017



List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2017
Number of Products under Development by Therapy Areas, H1 2017
Number of Products under Development by Indications, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017

COMPANIES MENTIONED

Astellas Pharma Inc Chugai Pharmaceutical Co Ltd Confluence Life Sciences Inc



I would like to order

Product name: Mitogen Activated Protein Kinase Kinase Kinase 7 (Transforming Growth Factor Beta

Activated Kinase 1 or MAP3K7 or EC 2.7.11.25) - Pipeline Review, H1 2017

Product link: https://marketpublishers.com/r/M9480A14242EN.html

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/M9480A14242EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature
	Custamer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

